Despite the compelling case for the further development of Rlip inhibitors, owing to the impressive broad-spectrum antitumor effects and the pleiotropic functions of Rlip in cancer cells, additional information is needed to understand the mechanisms underlying the striking transcriptomic and epigenetic changes. Here, RALBP1 is linked to cancer.